Citadel Advisors’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

Citadel Advisors’s Portfolio ARLZ Stock Details ARLZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-16,471	Closed	-$6K	–	10175
2018 Q2	$6K	Buy	16,471 +447	+3%	+$367	﹤0.01%	8734
2018 Q1	$24K	Sell	16,024 -7,937	-33%	-$13.9K	﹤0.01%	8100
2017 Q4	$34K	Buy	+23,961	New	+$39.3K	﹤0.01%	7745
2017 Q2	–	Sell	-83,537	Closed	-$121K	–	8647
2017 Q1	$179K	Buy	83,537 +33,293	+66%	+$125K	﹤0.01%	6605
2016 Q4	$221K	Buy	50,244 +4,755	+10%	+$22.6K	﹤0.01%	6164
2016 Q3	$221K	Buy	+45,489	New	+$207K	﹤0.01%	6175
2016 Q2	–	Sell	-13,933	Closed	-$49K	–	8005
2016 Q1	$49K	Buy	+13,933	New	+$71.8K	﹤0.01%	6258

Other funds holding ARLZ

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Citadel Advisors's ARLZ Position: Q3 2018 in Review

Citadel Advisors sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2018, closing a stake of 16,471 shares — an estimated $6K sold.

Citadel Advisors first reported a position in ARLZ in Q1 2016 and held it in 7 quarters. The position peaked at $221K in Q4 2016. 4 funds tracked by Wall St. Rank hold ARLZ as of Q3 2018.

Citadel Advisors reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
Citadel Advisors sold 16,471 Aralez Pharmaceuticals Inc. shares in Q3 2018, an estimated $6K.
Citadel Advisors first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 7 quarters.
Citadel Advisors's Aralez Pharmaceuticals Inc. position peaked at $221K in Q4 2016.
4 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2018.

Based on Citadel Advisors's 13F filing for Q3 2018, filed 13 Nov 2018.